Akero Therapeutics raised $65 million in series A financing to advance its lead program, long-acting fibroblast growth factor 21 (FGF21) analog, for the treatment of nonalcoholic steatohepatitis (NASH).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,